TCRX - NASDAQ
TScan Therapeutics, Inc.
$0.97
+0.14%TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
At a Glance
Live SnapshotTScan Therapeutics, Inc. Management Team
Dr. Gavin MacBeath Ph.D.
Chief Executive Officer & Director
Compensation
$1,025,727
Dr. Zoran Zdraveski J.D., Ph.D.
Chief Legal & Strategy Officer and Company Secretary
Compensation
$657,200
Dr. Chrystal U. Louis M.D., M.P.H.
Chief Medical Officer
Compensation
$550,125
Dr. Justin McCue Ph.D.
Chief Technology Officer
Dr. Stephen J. Elledge Ph.D.
Co-Founder & Chairman of Scientific Advisory Board
Mr. Tomasz Kula Ph.D.
Co-Founder & Member of Advisory Board
Mr. Jim Murray
Senior Vice President & Head of Development Operations
Mr. Ray Lockard M.B.A.
Senior Vice President & Head of Quality
Dr. Shrikanta Chattopadhyay M.D.
Senior Vice President & Head of Translational Medicine
Ms. Ann Hargraves
Senior Vice President of Human Resources
TScan Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $728K and sold $215K worth of TCRX shares, resulting in $514K of net buying activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
161.8K
145.53K
0
0.00
+146K
+$146K
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
402.0K
582.90K
70.0K
214.55K
+368K
+$368K
Top Buyers
Lynx1 Capital Management Lp
10 Percent Owner
$146K
Woods Keith
Director
$97K
Dorton Katina
Director
$97K
Gruia Gabriela
Director
$97K
Baker Bros. Advisors Lp
Director
$97K
Top Sellers
Dworak Leiden
Officer: Principal Accounting Officer
$215K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $514K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Insider Participation
5 insider buyers vs. 1 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
TCRX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 17, 2026 | May 20, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | May 14, 2025 | June 30, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 30, 2024 | June 12, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 25, 2023 | June 13, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 21, 2022 | June 01, 2022 | 2022 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.